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Introduction
Most lysosomal storage disorders affect the brain, including Mucopolysaccharidosis (MPS) Type II, or Hunter's syndrome. MPS-II is caused by mutations in the gene encoding for iduronate 2-sulfatase (IDS). MPS-II is treated with enzyme replacement therapy (ERT) using recombinant human IDS (Muenzer et al, 2006) . However, MPS-II severely affects the brain and spinal cord (Al Sawaf et al, 2008) , and ERT does treat the central nervous system (Wraith et al, 2008) , because IDS, like other large molecule pharmaceuticals, does not cross the blood-brain barrier (BBB). To provide a new treatment of the brain, the IDS enzyme was re-engineered as a brain-penetrating IgG-enzyme fusion protein. The mature human IDS was fused to the carboxyl terminus of each heavy chain of a genetically engineered monoclonal antibody (MAb) against the human insulin receptor (HIR), and this fusion protein was designated the HIRMAb-IDS fusion protein . The HIRMAb part of the fusion protein acts as a transport vector to ferry the fused IDS across the BBB via receptor-mediated transport on the endogenous BBB insulin receptor. The HIRMAb part of the fusion protein cross reacts with the insulin receptor in Old World primates, such as the Rhesus monkey , and the HIRMAb-IDS fusion protein rapidly penetrates the brain from blood in the Rhesus monkey .
However, the HIRMAb does not cross react with the insulin receptor in the mouse. There is no known MAb against the murine insulin receptor that could be used as a BBB transport vector in the mouse. BBB receptor-specific antibodies that can be used as brain transport vectors are limited to those antibodies that bind an endocytosing exofacial epitope on the alpha subunit of the murine insulin receptor. Therefore, a surrogate transport vector has been engineered for mouse studies, which is a chimeric MAb against the mouse transferrin receptor (TfR), and designated the cTfRMAb (Boado et al, 2009a) . The variable regions of the cTfRMAb are This article has not been copyedited and formatted. The final version may differ from this version. 
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5 derived from a rat TfRMAb, and the constant regions of the heavy and light chain are derived from mouse IgG1 and mouse kappa, respectively. Recently, a fusion protein of the cTfRMAb and murine iduronidase (IDUA), the enzyme mutated in MPS-I, Hurler's syndrome, was engineered . Chronic, twice-weekly intravenous treatment of Hurler mice with 1 mg/kg doses of the cTfRMAb-IDUA fusion protein resulted in a 73% decrease in brain lysosomal inclusion bodies, as well as reduction in glycosoaminoglycan (GAG) levels in peripheral tissues .
The purpose of the present study was to engineer a brain penetrating form of IDS that is active in the mouse, and to measure the brain uptake of the enzyme in the mouse. The amino terminus of mature IDS was fused to the carboxyl terminus of both heavy chains of the cTfRMAb, and this fusion protein is designated cTfRMAb-IDS. The present study also describes the cloning of an expression plasmid encoding human sulfatase modifying factor (SUMF)-1. The generation of IDS enzyme activity requires a post-translational modification of Cys 59 to N-formyl glycine, which is mediated by SUMF1 (Zito et al, 2005) . The role of coexpression of the genes encoding SUMF1 and the cTfRMAb-IDS fusion protein on IDS enzyme activity of the fusion protein was examined.
This article has not been copyedited and formatted. The final version may differ from this version. (Boado et al., 2009a) to form a single expression vector for the cTfRMAb heavy chain-IDS fusion protein, designated pCD-cTfRMAb-IDS. A tandem vector (TV) containing on a single plasmid DNA the expression cassettes encoding the cTfRMAb heavy chain-IDS fusion protein, the cTfRMAb light chain (LC), and the murine dihydrofolate reductase (DHFR), was engineered similar to a TV described previously . The complete cTfRMAb-IDS heavy chain open reading frame (orf) plus the bovine growth hormone (BGH) polyadenylation sequence was obtained from pCD-cTfRMAb-IDS by NotI-AfeI digestion and inserted into the NotI-HpaI sites of the TV. The TV coding for the cTfRMAb-IDS fusion protein was characterized by restriction endonuclease mapping using XhoI. The DNA sequence of all expression plasmids was confirmed by bi-directional DNA sequencing performed at Sequetech (Mountain View, CA) using custom ODNs synthesized at Midland.
Engineering of pSUMF1 expression vector. The complete orf of the human sulfatase modifying factor 1 (SUMF1) cDNA was produced by RT-PCR using ODNs generated from the nucleotide sequence of the human SUMF1 mRNA (NM_182760), including the forward ODN (AAAGAATTCTTGCCGCCACCATGGCTGCGCCCGCACTA) and reverse ODN 
7 (CTTAAGCTTTCAGTCCATAGTGGG). The forward ODN introduces an EcoRI site and a complete Kozak sequence followed by the methionine inititation codon of SUMF1. The reverse ODN ends with the stop codon of SUMF1, which is followed by a HindIII site. The RT-PCR was performed as previously described using human liver polyA+ RNA as template (Boado et al, 2008) . The PCR-generated ~1.2 kb SUMF1 cDNA was eluted following agarose gel electrophoresis and was digested with EcoRI and HindIII and inserted at the same restriction endonuclease sites to form the expression vector designated pSUMF1. In the vector, the SUMF1 orf is 5'-flanked by the cytomegalovirus (CMV) promoter, and 3'-flanked by the BGH polyadenylation sequence. Western. The immunoreactivity of the cTfRMAb-IDS fusion protein was compared with the cTfRMAb and with the HIRMAb-IDS fusion protein described previously (Boado et al, 2009a; Lu et al, 2011) . The HIRMAb-IDS fusion protein was produced in Chinese hamster ovary (CHO) cells grown in serum free medium as described previously . CHO-derived cTfRMAb, and mouse IgG1κ (Sigma), which is the isotype control of the cTfRMAb antibody (Boado et al, 2009a) .
Expression in COS cells
IDS enzyme assay. IDS enzyme activity was measured using a 2-step fluorometric enzymatic assay (Voznyi et al, 2001) , as described previously . The fusion protein was tested at concentrations ranging from 0.2 to 0.5 ug/mL in a volume of 100 uL. The IDS enzyme substrate, 4-methylumbelliferyl α-L-iduronide-2-sulphate (4-MUS), was purchased from Moscerdam Substrates (Rotterdam, The Netherlands). In the first step of the reaction, IDS converts 4-MUS to 4-methylumbelliferyl α-L-iduronide (MUBI). In the second step, iduronidase (IDUA) converts MUBI to 4-methylumbelliferone (4-MU), and the 4-MU is detected fluorometrically. The source of the IDUA was the HIRMAb-IDUA fusion protein produced from CHO cells as described previously (Boado et al, 2009b) . Franklin Lakes, NJ) and grown to confluency in DMEM medium with 10% fetal bovine serum.
The medium was removed, and the cells washed with phosphate buffered saline (PBS), followed by the addition of 1.0 mL/well of fresh DMEM containing 2 ug/mL cTfRMAb-IDS fusion protein followed by incubation at 37C for 2 hours. The medium was then removed, and the wells were washed with 1.5 mL/well of fresh serum free DMEM medium 3 times. Fresh DMEM medium with 10% FBS, 1.0 mL/well, was added and the dishes were incubated at 37C for 0, 2, 24, 48, 72, or 96 hours. At the end of the incubation, the medium was removed and the wells were washed with 1.5 mL/well cold PBS 3 times. The monolayer was lysed with the addition of 0.3 mL/well of 5 mM sodium acetate/pH=4.5/0.2% Triton X-100 followed by 3 successive freeze-thaw cycles. The lysate was centrifuged at 8,000 g for 10 minutes at 4C, and the supernatant was transferred to new tubes for measurement of intracellular protein with the bicinchoninic acid assay (Thermo Fisher Scientific, Rockford, IL), and intracellular IDS enzyme activity using the 2 step fluorometric assay described above. The intracellular IDS enzyme activity was expressed as nmol/hr/mg cellular protein. 
Radio
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11 transferrin receptor was purified from hybridoma generated ascites with protein G affinity chromatography, and was iodinated with chloramine T as described previously (Lee et al, 2000) .
Pharmacokinetics and brain uptake in the mouse. Adult male C57BL/6J mice, weighing 28 grams, were obtained from Jackson Labs (Bar Harbor, ME). All procedures were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the U.S. National Institutes of Health. Mice were anesthetized with intraperitoneal (IP) ketamine (100 mg/kg) and xylazine (10 mg/kg), and injected intravenously (IV) in the tail vein with 60 uL (10 uCi) of The plasma TCA-precipitable radioactivity, DPM/mL, was converted to % injected dose (ID)/mL, and the %ID/mL was fit to a bi-exponential equation,
This article has not been copyedited and formatted. The final version may differ from this version. The intercepts (A1, A2) and the slopes (k1, k2) were used to compute the pharmacokinetics parameters, including the median residence time (MRT), the central volume of distribution (Vc), the steady state volume of distribution (Vss), the area under the plasma concentration curve at 60 min (AUC), the steady state AUC (AUCss), and the systemic clearance (CL). Non-linear regression analysis used the AR subroutine of the BMDP Statistical Software. Data were weighted by 1/(%ID/mL) 2 .
The organ clearance (uL/min/g), also called the BBB permeability-surface area (PS) product, is computed from the terminal brain uptake (%ID/g) and the 60 min plasma AUC (%IDmin/mL) as follows:
The brain uptake was determined from total brain 3 H radioactivity, and the plasma AUC was determined from TCA-precipitable 3 H radioactivity.
Capillary depletion method. One cerebral hemisphere from each mouse was processed for the capillary depletion method as described previously (Triguero et al, 1990) , which separates the brain into 3 fractions: the total brain homogenate, the microvascular capillary pellet, and the post-vascular supernatant. The volume of distribution (VD) was determined for each of the 3 fractions from the ratio of total protein was 25 ± 1 nmol/hr/ug protein, whereas the IDS enzyme activity of the cTfRMAb-IDS fusion protein was 126 ± 1 nmol/hr/ug protein following co-lipofection of the fusion protein and SUMF1 (Table 1 ). The IDS enzyme activity of the HIRMAb-IDS fusion protein produced in CHO cells without co-expression of SUMF1 was 168 ± 1 nmol/hr/ug protein ( Table 1 ). The addition of the cTfRMAb-IDS fusion protein to the medium of mouse 3T3 fibroblasts resulted in 5-fold increase in intracellular IDS enzyme activity following a 2-hour exposure of the cells to the fusion protein ( Table 2) . The cells were then incubated in fusion protein-free fresh medium, and the increased IDS enzyme activity persisted for at least 96 hours after the initial single 2-hour exposure of the cells to the fusion protein (Table 2) . Linear regression analysis of the data in Table 2 showed the IDS enzyme activity decayed with a half-time of 1.7 days (r=0.96).
Fusion protein plasma pharmacokinetics in the mouse. The cTfRMAb-IDS fusion
protein was radiolabeled with the fusion protein from plasma after IV administration is plotted in Figure 5 . The plasma radioactivity decay curve was fit to a bi-exponential equation to yield the pharmacokinetics parameters shown in Table 3 . The cTfRMAb-IDS fusion protein was rapidly removed from plasma ( Figure 5 ). The plasma radioactivity that was precipitable by TCA was 88 ± 1, 83 ± 1, 79 ± 1, 78 ± 3, 74 ± 2, and 50 ± 3 %, respectively at 0.25, 2, 5, 15, 30, and 60 min after IV injection.
The rapid clearance of the fusion protein by plasma is also shown by the low 60 minute plasma AUC compared to the AUC of the OX26 mouse MAb against the rat TfR ( Figure 6A ). The OX26 MAb does not recognize the mouse TfR and is slowly cleared from plasma in the mouse (Lee et al, 2000) .
This article has not been copyedited and formatted. The final version may differ from this version. (Table 4 ). The VD of the fusion protein in the post-vascular supernatant, 102 ± 11 uL/gram, is 2.1-fold greater than the VD in the vascular pellet (Table 4) , indicating the majority of the cTfRMAb-IDS fusion protein had completed transcytosis through the BBB by 60 min after IV injection.
The uptake of the [ 3 H]-cTfRMAb-IDS fusion protein by brain was determined at 60 min after IV injection, and was 1.3 ± 0.1 %ID/gram brain ( Figure 6B ). The cTfRMAb-IDS fusion protein was also taken up by spinal cord (thoracic-cervical), and the uptake was 2.2 ± 0.2 %ID/gram (Table 5 ). The BBB permeability-surface area (PS) product of the cTfRMAb-IDS fusion protein in brain, which is equal to the ratio of the 60 min %ID/g ( Figure 6B ) and the 60 min plasma AUC ( Figure 6A ), is 3.3 ± 0.2 uL/min/g, which is high compared to the BBB PS product for the OX26 MAb ( Figure 6C ). The cTfRMAb-IDS fusion protein was rapidly taken up by peripheral tissues and the %ID/gram ranged from 0.60 ± 0.06 %ID/g for heart to 68 ± 17 %ID/g for spleen (Table 5 ).
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
The results of these studies are consistent with the following conclusions. First, a new IgG-IDS fusion protein has been engineered and expressed, the cTfRMAb-IDS fusion protein, which is specific for the mouse and retains both high affinity binding to the mouse TfR ( Figure   4 ) and high IDS enzyme activity (Tables 1-2) . Second, the cTfRMAb-IDS fusion protein is rapidly removed from blood ( Figure 5 , Table 3 ), and broadly distributed to brain, spinal cord, and peripheral tissues ( Figure 6 , Table 5 ). Third, the cTfRMAb-IDS fusion protein undergoes transcytosis across the BBB as shown by the capillary depletion method (Table 4) , and distributes to brain at rates that can restore a significant fraction of the IDS enzyme activity in brain.
The cTfRMAb-IDS fusion protein is formed by fusion of the mature 525 AA human IDS to the carboxyl terminus of each heavy chain of the cTfRMAb. Human IDS (Genbank NP_000193) and murine IDS (Genbank NP_034628) have a high, 88%, AA identity. The identity of the cTfRMAb-IDS fusion protein was confirmed by mouse IgG and human IDS Western blotting (Figure 3) , and the purity of the affinity purified fusion protein was confirmed by reducing SDS-PAGE (Figure 1 ). Non-reducing SDS-PAGE shows the fusion protein exists as a dimer at neutral pH. IDS and arysulfatase A (ASA) are members of a sulfatase family that form dimers at neutral pH and octamers at acidic pH (Lukatela et al, 1998) . These sulfatases require a post-translational modification for enzyme activity, whereby SUMF1 converts Cys 59 to N-formyl glycine (Zito et al, 2005) . Co-transfection with the SUMF1 gene and genes encoding the HIRMAb-IDS fusion protein is not necessary to produce maximal enzyme activity in stably transfected CHO cells . However, it is necessary to transiently co-transfect COS This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) .
The cTfRMAb-IDS fusion protein is rapidly removed from blood after IV injection with a systemic clearance of 8.2 ± 0.5 mL/min/kg (Table 3 ) and a systemic volume of distribution,
Vss, that exceeds the central plasma volume, Vc (Table 3 ). The systemic clearance of the HIRMAb-IDS fusion protein in the Rhesus monkey is 2.33 ± 0.04 mL/min/kg .
Similarly, lysosomal enzymes are rapidly removed from blood after IV injection. ASA, which shares AA homology with IDS (Franco et al, 1995) , has a plasma half-time of 40 minutes in the mouse (Matzner et al, 2005) . IDUA is rapidly removed from blood in the dog with a half-time of <30 minutes (Shull et al, 1994) . The rapid removal of the cTfRMAb-IDS fusion protein from blood is associated with partial degradation of the fusion protein, as represented by the decrease in plasma radioactivity that is precipitable by TCA (Results). However, previous work in the primate used gel filtration chromatography of plasma removed 2 hours after intravenous administration of the IgG-IDS to show the fusion protein in blood was intact .
The rapid clearance of the fusion protein from plasma parallels the widespread distribution of the fusion protein into peripheral tissues (Table 5 ). The high uptake of the cTfRMAb-IDS fusion protein by spleen (Table 5) is specific for the mouse, since the uptake of the HIRMAb-IDS fusion protein in the Rhesus monkey by spleen is comparable to the uptake by liver . The weight of the spleen in the mouse is 81 mg (unpublished observations); therefore, the total fraction of injected fusion protein taken up by the spleen in the mouse is <6 % of the injected dose (Table 5 ). In contrast to the rapid removal of the cTfRMAb-IDS fusion protein mouse fibroblasts for >96 hours after a single 2 hour exposure of the cells to the fusion protein (Table 2) , and the intracellular IDS enzyme activity decays with a half-time of 1.7 days (Results).
The principal finding of this study is the high uptake of the fusion protein by brain. The brain uptake of the cTfRMAb-IDS fusion protein by mouse brain is 1.3 ± 0.1 %ID/gram ( Figure   6 ). In contrast, the brain uptake in the mouse of recombinant IDS is 100-fold lower, or 0.013%
ID (Garcia et al, 2007) . The brain uptake in the mouse of the OX26 MAb, which is a brain blood volume marker in the mouse, is 0.06% ID/g (Lee et al, 2000) . Therefore, the mouse brain uptake of IDS of only 0.013% ID is evidence that IDS does not cross the BBB, and is confined to the blood volume of brain. The high rate of transport of the cTfRMAb-IDS fusion protein into brain is caused by the high affinity binding of the fusion protein to the TfR on the BBB. The affinity of the cTfRMAb-IDS fusion protein for the mouse TfR is equal to the affinity of the cTfRMAb (Figure 4) . Therefore, fusion of the IDS protein to the carboxyl terminus of the heavy chain of the cTfRMAb has no effect on binding to the mouse TfR. The TfR expressed on the BBB is a receptor-mediated transcytosis system, as demonstrated by electron microscopic immungold studies (Bickel et al, 1994) . In the present study, the capillary depletion method is used to demonstrate BBB transcytosis (Table 4) . Prior work has validated the capillary depletion method as a measure of BBB transcytosis using emulsion autoradiography of brain (Skarlatos et al, 1995) .
The brain uptake of the cTfRMAb-IDS fusion protein in the mouse is 1.3 ± 0.1 %ID/gram ( Figure 6B ) at an injection dose of 0.7 mg/kg (Methods). The IDS enzyme specific activity of the fusion protein is 126 ± 1 units/ug protein, where 1 unit = 1 nmol/hr (Table 1) .
Therefore, the IDS enzyme activity following the IV injection of a dose of 1 mg/kg of the This article has not been copyedited and formatted. The final version may differ from this version. (Tomatsu et al, 2007) . Therefore, a 1 mg/kg dose of the cTfRMAb-IDS fusion protein is predicted to replace 18% of the endogenous IDS enzyme activity in brain. This dosing is expected to be therapeutic in the brain, since the replacement of only 1-2% of lysosomal enzyme activity reverses lysosomal inclusion lesions in tissues (Muenzer and Fisher, 2004) .
In summary, the cTfRMAb-IDS fusion protein is a new form of the IDS enzyme that is This article has not been copyedited and formatted. The final version may differ from this version. 
